Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Receives Consensus Rating of “Strong Buy” from Analysts

Shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price target of $9.75 for the company and are expecting that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also given Cumberland Pharmaceuticals an industry rank of 65 out of 255 based on the ratings given to related companies.

CPIX has been the subject of several recent research reports. B. Riley raised their price target on Cumberland Pharmaceuticals from $9.00 to $9.75 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research cut Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 21st. Finally, ValuEngine downgraded Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th.

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in shares of Cumberland Pharmaceuticals by 13.0% during the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after buying an additional 50,800 shares in the last quarter. BlackRock Inc. grew its stake in Cumberland Pharmaceuticals by 17.2% in the 2nd quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after acquiring an additional 48,753 shares during the period. Acadian Asset Management LLC raised its holdings in Cumberland Pharmaceuticals by 6.9% in the 2nd quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock valued at $665,000 after acquiring an additional 6,765 shares during the last quarter. Dalton Greiner Hartman Maher & Co. acquired a new position in Cumberland Pharmaceuticals in the 3rd quarter valued at $528,000. Finally, Bailard Inc. purchased a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth $92,000. 29.52% of the stock is currently owned by institutional investors.

CPIX traded down $0.11 during midday trading on Tuesday, reaching $5.13. 17,962 shares of the company’s stock were exchanged, compared to its average volume of 19,412. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.35 and a quick ratio of 1.88. The stock has a market capitalization of $77.89 million, a PE ratio of -42.75 and a beta of 0.10. The business’s 50-day moving average price is $5.22 and its 200 day moving average price is $5.66. Cumberland Pharmaceuticals has a 1-year low of $4.19 and a 1-year high of $6.99.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.11 by ($0.10). Cumberland Pharmaceuticals had a positive return on equity of 6.76% and a negative net margin of 10.13%. The business had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $12.65 million. As a group, analysts expect that Cumberland Pharmaceuticals will post 0.15 EPS for the current fiscal year.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.